Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1996 1
1998 4
1999 3
2000 9
2001 10
2002 11
2003 9
2004 16
2005 12
2006 21
2007 10
2008 18
2009 14
2010 14
2011 12
2012 3
2013 1
2014 4
2015 3
2016 6
2017 5
2018 3
2019 1
2020 1
2021 1
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Results by year

Filters applied: . Clear all
Page 1
Significance, detection and markers of disseminated breast cancer cells.
Lacroix M. Lacroix M. Endocr Relat Cancer. 2006 Dec;13(4):1033-67. doi: 10.1677/ERC-06-0001. Endocr Relat Cancer. 2006. PMID: 17158753 Review.
DTC markers are listed and the most currently used of them (KRT19, CEACAM5, TACSTD1, MUC1, EGFR, ERBB2, SCGB2A2, SCGB2A1, SCGB1D2, PIP, SBEM, TFF1, TFF3, ANKRD30A, SPDEF, ESR1, SERPINB5 and GABRP) are discussed, notably on the basis of recent data on breast tumour p …
DTC markers are listed and the most currently used of them (KRT19, CEACAM5, TACSTD1, MUC1, EGFR, ERBB2, SCGB2A2, SCGB2A1, SCGB1D2, PI …
Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies.
Zafrakas M, Petschke B, Donner A, Fritzsche F, Kristiansen G, Knüchel R, Dahl E. Zafrakas M, et al. BMC Cancer. 2006 Apr 9;6:88. doi: 10.1186/1471-2407-6-88. BMC Cancer. 2006. PMID: 16603086 Free PMC article.
BACKGROUND: Mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2), two members of the secretoglobin superfamily, are known to be co-expressed in breast cancer, where their proteins form a covalent complex. ...In these four tissues the expression pattern of mammaglobin …
BACKGROUND: Mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2), two members of the secretoglobin superfamily, are known to be co-expr …
Mammaglobin 1 promotes breast cancer malignancy and confers sensitivity to anticancer drugs.
Picot N, Guerrette R, Beauregard AP, Jean S, Michaud P, Harquail J, Benzina S, Robichaud GA. Picot N, et al. Mol Carcinog. 2016 Jul;55(7):1150-62. doi: 10.1002/mc.22358. Epub 2015 Jul 24. Mol Carcinog. 2016. PMID: 26207726
We have thus set out to conduct a functional evaluation of the molecular and cellular roles of MGB1 in breast cancer processes leading to disease progression. Using a series of breast cancer cell models with conditional MGB1 expression, we demonstrate that MGB1 prom …
We have thus set out to conduct a functional evaluation of the molecular and cellular roles of MGB1 in breast cancer processes leadin …
Preferential expression of NY-BR-1 and GATA-3 in male breast cancer.
Biserni GB, Di Oto E, Moskovszky LE, Foschini MP, Varga Z. Biserni GB, et al. J Cancer Res Clin Oncol. 2018 Feb;144(2):199-204. doi: 10.1007/s00432-017-2542-z. Epub 2017 Nov 7. J Cancer Res Clin Oncol. 2018. PMID: 29116378 Free PMC article.
BACKGROUND: Male breast cancer is an uncommon disease often discovered in advanced stage; thus, in the setting of metastatic adenocarcinoma, breast origin must be taken to account. Breast markers as NY-BR-1, GATA-3, mammaglobin, and BRST-2 are established too …
BACKGROUND: Male breast cancer is an uncommon disease often discovered in advanced stage; thus, in the setting of metastatic adenocar …
Mammaglobin and lipophilin B expression in breast tumors and their lack of effect on breast cancer cell proliferation.
Sjödin A, Ljuslinder I, Henriksson R, Hedman H. Sjödin A, et al. Anticancer Res. 2008 May-Jun;28(3A):1493-8. Anticancer Res. 2008. PMID: 18630503 Free article.
BACKGROUND: Mammaglobin (SCGB2A2) and lipophilin B (SCGB1D2) are members of the secretoglobin polypeptide family. ...Ectopic overexpression of mammaglobin and lipophilin B did not affect the cell proliferation rate of Hs578T breast carcinoma cells in vitro. CONCLUSI …
BACKGROUND: Mammaglobin (SCGB2A2) and lipophilin B (SCGB1D2) are members of the secretoglobin polypeptide family. ...Ectopic overexpr …
Relationship between mammaglobin expression and estrogen receptor status in breast tumors.
Guan XF, Hamedani MK, Adeyinka A, Walker C, Kemp A, Murphy LC, Watson PH, Leygue E. Guan XF, et al. Endocrine. 2003 Aug;21(3):245-50. doi: 10.1385/ENDO:21:3:245. Endocrine. 2003. PMID: 14515009
Mammaglobin (SCGB2A2) is a breast-specific member of the secretoglobin (SCGB) gene family. ...As estrogen and antiestrogen treatment of estrogen-positive breast cancer cell lines does not modify SCGB2A2 expression we suggest that SCGB2A2 may be …
Mammaglobin (SCGB2A2) is a breast-specific member of the secretoglobin (SCGB) gene family. ...As estrogen and antiestrogen tre …
Mammaglobin 1: not only a breast-specific and tumour-specific marker, but also a hormone-responsive endometrial protein.
Classen-Linke I, Moss S, Gröting K, Beier HM, Alfer J, Krusche CA. Classen-Linke I, et al. Histopathology. 2012 Nov;61(5):955-65. doi: 10.1111/j.1365-2559.2012.04290.x. Epub 2012 Sep 20. Histopathology. 2012. PMID: 22994369
AIMS: The secretoglobin mammaglobin 1 (MGB1) is strongly expressed in breast tumours, and is therefore used to detect breast cancer metastases, although it has also been detected in other tissues. ...MGB1 was detected in human endometrial tissue, with peak expressio …
AIMS: The secretoglobin mammaglobin 1 (MGB1) is strongly expressed in breast tumours, and is therefore used to detect breast c …
Mammaglobin, a breast-specific gene, and its utility as a marker for breast cancer.
Fleming TP, Watson MA. Fleming TP, et al. Ann N Y Acad Sci. 2000;923:78-89. doi: 10.1111/j.1749-6632.2000.tb05521.x. Ann N Y Acad Sci. 2000. PMID: 11193781
As an initial step to determine mammaglobin's clinical utility as a breast tumor marker, we evaluated the frequency and specificity with which mammaglobin expression could be detected in primary breast tumors, metastatic breast tumors, and breast tumor …
As an initial step to determine mammaglobin's clinical utility as a breast tumor marker, we evaluated the frequency and specificity w …
Targeted doxorubicin delivery and release within breast cancer environment using PEGylated chitosan nanoparticles labeled with monoclonal antibodies.
Helmi O, Elshishiny F, Mamdouh W. Helmi O, et al. Int J Biol Macromol. 2021 Aug 1;184:325-338. doi: 10.1016/j.ijbiomac.2021.06.014. Epub 2021 Jun 10. Int J Biol Macromol. 2021. PMID: 34119547
Breast cancer has been one of the top chronic and life-threatening diseases worldwide. ...To provide high drug selectivity, CSNPs functionalized with two different types of breast cancer-specific monoclonal antibodies (mAb); anti-human mammaglobin (Anti-hMAM) and an …
Breast cancer has been one of the top chronic and life-threatening diseases worldwide. ...To provide high drug selectivity, CSNPs fun …
GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y, Lu S, Zeng W, Xie S, Xiao S. Yang Y, et al. Ann Diagn Pathol. 2017 Feb;26:1-5. doi: 10.1016/j.anndiagpath.2016.09.011. Epub 2016 Sep 26. Ann Diagn Pathol. 2017. PMID: 28038704
In this study, we undertook a comparative study of the marker GATA3 and GCDFP15 and MGB in clinically useful groups of paired primary and metastatic breast cancer. We retrieved 64 cases of matched primary and metastatic breast cancer from the surgical pathology arch …
In this study, we undertook a comparative study of the marker GATA3 and GCDFP15 and MGB in clinically useful groups of paired primary and me …
174 results